LFWD Share Price Performance
US$0
-14.88 (-100.00%)
Price US$0
Fair ValueUS$20.00
Share Pricen/a
Narrative Update • May 16
Lifeward Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
LFWD Community Narratives
AN
Fair Value
·Fair Value US$20 65.1% undervalued intrinsic discount
Expanding International Healthcare Access And Efficiencies Will Unlock Value
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$30 76.7% undervalued intrinsic discount
Global Aging And Robotics Integration Will Unlock New Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$10 30.2% undervalued intrinsic discount
Slow Medicare Reimbursements Will Undermine Efficiency But Foster Resilience
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Expanding International Healthcare Access And Efficiencies Will Unlock Value
Lifeward sells devices that help people with mobility and rehab, and it could benefit as more patients gain access to care and demand rises with an aging population. But uneven insurance payments, slow customer adoption, and the need to raise more cash could derail the path to steadier growth.Read more
AN
US$20
65.1% undervalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
2.73x
Price in 2029
US$14.15
Slow Medicare Reimbursements Will Undermine Efficiency But Foster Resilience
Key Takeaways Heavy reliance on a few flagship products and reimbursement delays expose Lifeward to margin pressure, cash flow risks, and regulatory or competitive setbacks. Expansion opportunities and operational improvements are offset by global pricing pressure, high upfront costs, and required ongoing investment, delaying meaningful profitability.Read more
AN
US$10
30.2% undervalued intrinsic discount
Fair Value
Profit Margin
12.79%
Future PE
1.77x
Price in 2029
US$7.16
Global Aging And Robotics Integration Will Unlock New Markets
Key Takeaways Lifeward is positioned for significant growth from increased global demand, product innovation, and operational scaling, potentially outpacing current analyst expectations on both revenue and margins. Strategic advantages in AI integration, patient-focused leadership, and proven international expansion provide unique access to high-value market segments and sustainable long-term profitability.Read more
AN
US$30
76.7% undervalued intrinsic discount
Fair Value
Profit Margin
12.7%
Future PE
2.78x
Price in 2029
US$21.41
Trending Discussion
Recently Updated Narratives
AN
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Fair Value: US$20 65.1% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Fair Value: US$10 30.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Fair Value: US$30 76.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Lifeward Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -9.19
- 36.55%
- -123.66%
- 115.7%
About LFWD
- Founded
- 2001
- Employees
- 81
- CEO
- WebsiteView website
Lifeward Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, Germany, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices for individuals with spinal cord injury; ReStore Exo-Suit, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals’ post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as ReWalk Robotics Ltd. and changed its name to Lifeward Ltd. in September 2024. Lifeward Ltd. was incorporated in 2001 and is based in Yokneam Illit, Israel.
